Aurobindo Pharma receives USFDA approval for Deflazacort Tablets

Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), EMFLAZA® tablets 6 mg, 18 mg, 30 mg, and 36 mg of PTC Therapeutics Inc. The product will be launched in February 2024 and has an estimated market size of USS 67 million for the three months ending September 2023.,